

Common Fusion Transcripts Identified in Colorectal Cancer Cell Lines by High-Throughput RNA Sequencing^{1,2}

Torfinn Nome^{*,†}, Gard O.S. Thomassen^{*,†}, Jarle Bruun^{*,†}, Terje Ahlquist^{*,†}, Anne C. Bakken^{*,†}, Andreas M. Hoff^{*,†}, Torleiv Rognum^{†,§}, Arild Nesbakken^{†,||}, Susanne Lorenz^{#,**}, Jinchang Sun^{#,**}, João Diogo Barros-Silva^{†,††,‡‡}, Guro E. Lind^{*,†}, Ola Myklebost^{#,**}, Manuel R. Teixeira^{†,††,‡‡,§§}, Leonardo A. Meza-Zepeda^{#,**}, Ragnhild A. Lothe^{*,†} and Rolf I. Skotheim^{*,†}

^{*}Department of Cancer Prevention, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; [†]Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway; [‡]University of Oslo, Oslo, Norway; [§]Department of Forensic Pathology and Clinical Forensic Medicine, Division for Forensic Medicine, The Norwegian Institute of Public Health, Oslo, Norway; ^{||}Department of Gastrointestinal Surgery, Aker University Hospital, Oslo University Hospital, Oslo, Norway; [#]Department of Tumor Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; ^{**}Genomics Core Facility, Department of Molecular Biosciences, University of Oslo, Oslo, Norway; ^{††}Department of Genetics, Portuguese Oncology Institute, Porto, Portugal; ^{‡‡}Cancer Genetics Group, Research Centre of the Portuguese Oncology Institute, Porto, Portugal; ^{§§}Institute of Biomedical Sciences, University of Porto, Porto, Portugal

Abstract

Colorectal cancer (CRC) is the third most common cancer disease in the Western world, and about 40% of the patients die from this disease. The cancer cells are commonly genetically unstable, but only a few low-frequency recurrent fusion genes have so far been reported for this disease. In this study, we present a thorough search for novel fusion transcripts in CRC using high-throughput RNA sequencing. From altogether 220 million paired-end sequence reads from seven CRC cell lines, we identified 3391 candidate fused transcripts. By stringent requirements, we nominated 11 candidate fusion transcripts for further experimental validation, of which 10 were positive by reverse transcription–polymerase chain reaction and Sanger sequencing. Six were intrachromosomal fusion transcripts, and interestingly, three of these, *AKAP13-PDE8A*, *COMMD10-AP3S1*, and *CTB-35F21.1-PSD2*, were present

Address all correspondence to: Dr philos Rolf I. Skotheim, Department of Cancer Prevention, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, NO-0424 Oslo, Norway. E-mail: rolf.i.skotheim@rr-research.no

¹This study was funded by grants from the Norwegian Cancer Society (PR-2006-0442 to R.A.L. and PR-2007-0166 to R.I.S.). Instrumentation for high-throughput sequencing has been financed by the Norwegian Radium Hospital Legacies. The authors declare that they have no competing interests.

²This article refers to supplementary materials, which are designated by Tables W1 to W8 and Figure W1 and are available online at www.transonc.com.

Received 10 June 2013; Revised 24 July 2013; Accepted 25 July 2013

in, respectively, 18, 18, and 20 of 21 analyzed cell lines and in, respectively, 18, 61, and 48 (17%-58%) of 106 primary cancer tissues. These three fusion transcripts were also detected in 2 to 4 of 14 normal colonic mucosa samples (14%-28%). Whole-genome sequencing identified a specific genomic breakpoint in *COMMD10-AP3S1* and further indicates that both the *COMMD10-AP3S1* and *AKAP13-PDE8A* fusion transcripts are due to genomic duplications in specific cell lines. In conclusion, we have identified *AKAP13-PDE8A*, *COMMD10-AP3S1*, and *CTB-35F21.1-PSD2* as novel intrachromosomal fusion transcripts and the most highly recurring chimeric transcripts described for CRC to date. The functional and clinical relevance of these chimeric RNA molecules remains to be elucidated.

Translational Oncology (2013) 6, 546-553

Introduction

Colorectal cancer (CRC) is a global health problem with a high incidence and mortality. It is the second most common cancer type in Europe, and only lung cancer causes more cancer deaths per year [1]. The management of CRC is therefore in need of improved biomarkers for detection, monitoring, and prognostication, as well as prediction of treatment response [2]. Furthermore, effective targeted therapies are warranted for this disease [3]. A promising strategy to meet these demands is to identify highly cancer-specific molecules.

Gene expression profiling has been used to identify genes with ectopic expression in cancer. However, the efforts so far have not been sufficient for development of any differentially expressed genes into clinically useful biomarkers, probably because the gene expression is not specific enough for the malignant cells. Differential pre-mRNA processing adds an additional layer of complexity, and dysregulation of alternative splicing and promoter switches may yield cancer-specific transcripts and protein isoforms [4]. Chimeric fusion transcripts represent another source of common cancer-specific RNA and proteins and have, for other cancer types, been useful in both cancer detection and monitoring of patients with cancer, as well as being direct targets for treatment. Most recurrent fusion genes previously identified have been found from studies of hematological malignancies and sarcomas. Among the four most common carcinomas, the surprising discovery of the *TMPRSS2-ERG* fusion gene present in about half of all prostate cancers was reported in 2005 [5]. Later, several additional recurrent fusion genes in prostate cancer have been reported [6-10]. Furthermore, but with lower frequencies, fusion genes involving the targetable *ALK*, *ROS1*, and *RET* partners have been found in lung cancer [11-14]. In breast cancer, a recurrent fusion with a low frequency, *SEC16A-NOTCH1*, has been reported [15]. For CRC, there are three recent reports of recurrent fusion transcripts [13,16,17], but all of them occur in low frequencies.

Fusion transcripts are often produced after chromosomal rearrangements but can also be generated by RNA polymerase read-throughs and trans-splicing of pre-mRNA. Recently, there have been reports that chimeric fusion transcripts, generated by polymerase read-throughs and trans-splicing, are common within prostate cancers [18,19]. Low, but detectable, levels of *SLC45A3-ELK4* mRNA was found in both benign and malignant prostate tissues, with higher expression of the fusion transcript in the malignant tissues [9]. Interestingly, there is also evidence for chimeric transcripts to be frequent and nonrandom within nonmalignant cells [20], and protein products from chimeric transcripts were recently reported to be commonly present in human cells [21]. Chimeric transcripts were recently also shown to have a regulatory role of growth in

cancer cells [22]. The recent ENCODE transcriptome study suggests that the definition of a gene should be redefined on the basis of their findings of widespread overlapping of neighboring gene regions [23]. Furthermore, presence of fusion transcripts in nonmalignant cells, generated by trans-splicing, has been demonstrated to guide chromosomal rearrangements involving the same fusion partners in endometrial stromal tumors [24]. Regardless of the mechanisms, fusion transcripts may encode cancer-specific chimeric proteins, which are promising as biomarkers and also as targets for therapy.

Identification of recurrent fusion transcripts in CRC may aid the development of improved diagnostics and tailored treatment. In this study, we have identified novel fusion transcripts from colon cancer cell lines by use of paired-end RNA sequencing and shown their presence also in malignant, and sometimes nonmalignant, tissue from the large bowel.

Methods

Colon Cancer Cell Lines and Clinical Tissue Samples

Seven colon cancer cell lines were included in the RNA sequencing analyses. HCT15, SW48, HCT116, and RKO are known to be of the microsatellite instability (MSI) phenotype, and HT29, SW480, and LS1034 are microsatellite stable (MSS) [25]. Fourteen additional colon cancer cell lines were added to the validation panel (SW620, LoVo, Co115, Colo320, IS1, IS2, IS3, TC7, TC71, FRI, V9P, LS174T, EB, and NCI-H508). The cell lines have been obtained from Dr Richard Hamelin (INSERM, Paris, France) and American Type Culture Collection (Manassas, VA). Culturing conditions for the individual cell lines will be given on request. The cell lines have previously been karyotyped, and copy number was assessed by comparative genomic hybridization (CGH). Identities of the cell lines were verified by the AmpFISTR Identifiler PCR Amplification Kit (Applied Biosystems by Life Technologies, Carlsbad, CA). Cell lines were harvested at a time point shortly before confluence was reached, and RNA was isolated using TRIzol (Life Technologies Inc, Rockville, MD). Quantity was measured using NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA), and quality was evaluated with Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA).

Tissue samples were collected from 106 patients treated surgically for CRC in hospitals in the Oslo region, Norway. The CRCs were enriched for clinical stages II and III (52 stage II, 53 stage III, and 1 stage IV CRCs) and included both MSI and MSS types [$n = 20$ and 85 (one sample not scored), respectively]. A summary of clinical data for the patients can be found in Table W1 (Supplementary Materials).

For 14 patients, corresponding normal colonic mucosa was taken from visually disease-free areas. Tumors were staged according to the American Joint Cancer Committee/Union for International Cancer Control. Status for MSI, gene mutations (within *KRAS*, *BRAF*, *PIK3CA*, *PTEN*, and *TP53*), and transcriptome instability were obtained from previous publications [26–28]. The research biobanks have been registered according to national legislation, and the study has been approved by the Regional Committee for Medical Research Ethics (Biobank 2781; REK South-East S-09282c2009/4958). Informed consent was obtained from patients enrolled to the study. RNA from the tissue samples was isolated by using AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, CA). Quantity and quality were measured and evaluated as described above. Further, a panel of 20 normal tissues from different organs and tissue types was included (FirstChoice Human Normal Tissue Total RNA, each has a pool of RNA from at least three individuals, with the exception of an individual sample from the stomach; Ambion, Applied Biosystems by Life Technologies, Carlsbad, CA).

High-Throughput Paired-End RNA Sequencing

Library construction followed the standard Illumina mRNA library preparation (icom.illumina.com, 2009; Illumina Inc, San Diego, CA), including poly-A mRNA isolation, fragmentation, and gel-based size selection. Shearing to about 250-bp fragments was achieved using the Covaris S2 focused-ultrasonicator (Covaris Inc, Woburn, MA). Sequencing was performed according to the paired-end RNA sequencing protocols from Illumina for Solexa sequencing on a Genome Analyzer IIx with paired-end module (Illumina Inc). For all seven cell lines, 23 to 38 million clusters were generated (Table W2; Supplementary Materials). Seventy-six bps were sequenced, from each side of a fragment about 250 bp long.

Gene Fusion Prediction and Gene Expression

Only reads marked by the Illumina pipeline (Bustard.py, OLB 1.6.0 and 1.8.0) as *passed filtering* were used in the analysis. We used the fusion discovery software tool deFuse [29], version 0.2.1, with hg19 sequence reference and Ensembl release 58 annotation databases, to assist in locating potential gene fusions. Several filtering steps of the fusions were performed. The first step included filtering against fusions identified in normal cells and tissues. These were identified from analysis of the Illumina Human Body Map v2 data set, including paired-end RNA sequencing data from 16 nonmalignant sample types, including normal colonic mucosa (ArrayExpress accession ID E-MTAB-513 and European Nucleotide Archive study accession ID ERP000546). The deFuse software was applied with the same settings as for analyzing the seven colon cancer cell lines. Fusions from the 16 cell and tissue types were pooled together and defined as normal tissue fusions. The second filtering step removed fusions where at least one of the fusion partners was annotated as a ribosomal gene (as listed in Biomart Ensembl release 60, GO term 0005840). The third step removed promiscuous fusions where one of the genes had multiple partners within the same cell line. The fourth step removed intrachromosomal fusions where the gene partners were located less than 100 kbp apart. The fifth, and final, step removed genes where the chimeric breakpoint sequences were introns or intraxonic, leaving only fusion transcripts with intact exon-exon boundaries, using predominantly consensus splice sites. Gene expression levels were computed by using Cufflinks v1.1.0 [30], with the Illumina iGenomes Ensembl GRCh37 data set (2011-06-20) as reference, on reads aligned with TopHat v1.3.3 [31] and Bowtie v0.12.5 [32]. Coverage and anno-

tation plots were created using R [33] and the GenomeGraphs [34] package in Bioconductor [35].

Reverse Transcription–Polymerase Chain Reaction and cDNA Sequencing

First-strand cDNA synthesis was performed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA), and reverse transcription–polymerase chain reaction (RT-PCR) with HotStart Taq DNA Polymerase Kit (Qiagen) was performed to validate the existence of the nominated fusion transcripts. Primers were designed to span the fusion breakpoints using the Primer3 software [36] with default parameters (primer sequences are shown in Table W3; Supplementary Materials). The PCR products were run on a 2% agarose gel containing ethidium bromide. When only one band was present after electrophoresis, the PCR product was cleaned using ExoSAP-IT (GE Healthcare, Little Chalfont, United Kingdom) before sequencing. When several bands were present, each was cut and eluted using the MinElute Gel Extraction Kit (Qiagen). All samples were further sequenced (BigDye with ABI 3730 DNA analyzer; Applied Biosystems).

Whole-Genome Paired-End DNA Sequencing

Whole-genome paired-end sequencing was performed by BGI Hong Kong (Hong Kong, China) on the four cell lines with confirmed fusion transcripts (HCT15, HCT116, HT29, and SW480) to an average coverage of $\times 30$. Around 850 million 100-bp paired-end reads were produced for each cell line. The sequence reads were aligned by BWA version 0.6.1 [37] against hg19, and the loci of the validated fusion transcripts were visualized in the Integrative Genomics Viewer [38]. Genomic breakpoints were identified by nFuse version 0.2.0 [39].

Fluorescence in situ Hybridization (FISH)

To detect chromosomal rearrangements involving *AKAP13* and *PDE8A*, we used a triple color probe FISH strategy flanking the aforementioned genes. Bacterial artificial chromosome (BAC) clones targeting the 5' region of *PDE8A* (CTD-2253L13), the 3' region of *AKAP13* (RP11-296P8 and CTD-3247B18), and the 200-kb region between the two genes (CTD-2222G4) were selected using the UCSC Human Genome Browser and obtained from the BACPAC Resources Center (Oakland, CA). BAC DNA was extracted using the Plasmid DNA Purification Kit (MACHEREY-NAGEL GmbH KG, Duren, Germany) and amplified using the GenomiPhi V2 DNA Amplification Kit (WGA kit; GE Healthcare) according to the manufacturer's instructions. BAC DNA was labeled with SpectrumGreen (CTD-2222G4)–, SpectrumRed (CTD-2253L13)–, and SpectrumAqua (CTD-3247B18, RP11-296P8)–conjugated nucleotides by nick translation according to the manufacturer's instructions (Nick Translation DNA Labelling System; Enzo Life Sciences, Farmingdale, NY). Adequate mapping and probe specificity of all BAC clones was confirmed by hybridization onto normal human metaphases. SW480 metaphase spreads were obtained according to standard procedures.

Results

Identification of Fusion Transcripts and Gene Expression from Paired-End RNA Sequencing Data

Altogether 220 million paired-end sequence reads were generated from seven colon cancer cell lines (Table W2; Supplementary Materials;

European Nucleotide Archive study accession ID ERP002049). From these, 3391 candidate fusion transcripts were identified with at least five-fold coverage of sequence pairs across the fusion partners and at least three individual sequence reads spanning the actual breakpoint. Subsequent filtering resulted in a set of 11 fusion transcripts reliably nominated for experimental validation (Figure 1 and Table W4, A and B; Supplementary Materials). Briefly, first, 644 fusions were removed, because they were also identified in a set of 16 miscellaneous types of normal cells and tissues by use of the same data processing algorithm as for the cancer cell lines. The second filter removed 1419 fusions where at least one of the partner genes encoded ribosomal proteins, known to be frequent artifacts. The third filter removed 1116 fusions in which a common partner in a number of different fusions in the same sample was included. The fourth filter removed 39 of the remaining chimeric sequences where the gene partners were localized within less than 100 kb on the same chromosome, likely to be read-throughs. The fifth filter removed 162 additional chimeric sequences and ensured that only chimeric sequences with exact whole exons at either side of the breakpoints were included, preserving consensus splice sites.

Experimental Verification and Exploration within Additional Colon Cancer Cell Lines

The presence of the 11 CRC fusion transcripts selected for experimental validation were verified by RT-PCR of RNA from the same cell lines in which they were identified, and the junction was confirmed by Sanger sequencing (Table 1). Four of these were interchromosomal, whereas six were intrachromosomal. For all experimentally verified fusions, RT-PCR spanning the same exon-exon boundaries as initially identified was performed on a set of 19 colon cancer cell lines (including the seven analyzed by RNA sequencing). For three of the 10 fusion transcripts multiple positive bands were observed (86%-95% of cell lines; Table 2), and for these, an additional nested PCR primer pair was designed to ensure specificity of the analysis. The three recurrent fusion transcripts were *AKAP13-PDE8A* (86%; Figure 2), *COMMD10-AP3S1* (95%; Figure 3), and *CTB-35F21.1-PSD2* (86%; Figure W1; Supplementary Materials). The other fusion tran-

Table 1. Fusion Transcripts Experimentally Validated by RT-PCR and Sanger Sequencing.

Fusion Gene	Chromosome Bands		Cell Line	Distance (kb)*	Genomic Breakpoint [†]
Interchromosomal					
<i>SLC39A14-TSPAN15</i>	8p21.3	10q22.1	HT29		N
<i>NCOA3-SPINT1</i>	20q12	15q13.3	HCT15		N
<i>GRIN2B-CYP4F3</i>	12p12	19p12.12	SW480		Y
<i>FAM96A-STIM1</i>	15q22.31	11p15.5	SW480		Y
Intrachromosomal					
<i>PRMT1-FLT3LG</i>	19q13.33	19q13.33	HCT15	214	N
<i>MGRN1-C16orf96</i>	16p13.3	16p13.3	HCT15	134	Y
<i>COMMD10-AP3S1</i>	5q23.1	5q22.3	HCT116	198	Y
<i>SPAG9-MBTD1</i>	17q21.33	17q21.33	HCT116	298	Y
<i>AKAP13-PDE8A</i>	15q25.3	15q25.3	SW480	556	N
<i>CTB-35F21.1-PSD2</i>	5q31.2	5q31.2	SW480	160	N

*Distance is the outer distance between the two genes.
†Predicted genomic breakpoint by nFuse.

scripts were positive in one or two cell lines each (Table W5; Supplementary Materials).

The *AKAP13-PDE8A* locus was analyzed by three-color interphase and metaphase FISH on the SW480 cell line, showing predominantly five signals per cell (two in seemingly normal chromosome 15 and three in aberrant chromosomes), but no evidence of chromosome rearrangement splitting signals from within or between *AKAP13* and *PDE8A*. However, from whole-genome sequencing data of SW480, we found an increased coverage in the particular genomic segment from intron 2 in *PDE8A* to intron 1 in *AKAP13*, involving the exact set of exons corresponding to the observed *AKAP13-PDE8A* fusion transcript (Figure 2B), indicating that there is a duplication of that small genomic segment (below the resolution level of FISH analysis) that juxtaposes exon 1 of *AKAP13* 5' to exon 3 of *PDE8A* (Figure 2). Theoretically, this fusion gene could also be originated by translocation or insertion between the two chromosome 15 regions, but these two mechanisms do not generate copy number changes and they would have been detectable by the FISH strategy we used.

Out of the additional experimentally verified fusion transcripts, a similar increased coverage from the whole-genome sequence data for the corresponding cell line was found for the *COMMD10-AP3S1* region in the HCT116 cell line (Figure 3B).

By analyzing the whole-genome sequencing data using nFuse [39], we identified a genomic breakpoint between the genes *COMMD10* and *AP3S1* and also of four additional fusion transcripts (Table 1). We performed genomic PCR of the predicted breakpoint of the *COMMD10-AP3S1* fusion on the set of 19 colon cancer cell lines. Only HCT116, from which both the fusion transcript and the genomic breakpoint were originally identified, harbored this exact breakpoint.

The sequenced cell lines have also previously been karyotyped [25]. From this, we do not find cytogenetic evidence of genomic breakpoints at the loci of the fusion partner genes. However, the reported intrachromosomal fusion transcripts have also proximal loci that are visible at the cytogenetic level.

Validation in Clinical Specimens

Altogether 106 clinical CRC specimens, 14 with corresponding normal colonic mucosa, were analyzed for the presence of any of the 10 fusion transcripts. To ensure specificity of the products, nested PCR primers were generated for the three with multiple bands in the cell lines (*AKAP13-PDE8A*, *COMMD10-AP3S1*, and *CTB-35F21.1-PSD2*). A PCR-on-PCR protocol was applied for the remaining seven




Figure 1. The identified fused sequences were filtered in a stepwise manner for nomination of fusion transcripts for further experimental validation.

Table 2. Nested PCR Performed on Two Patient Sample Series, One of Them Paired with Normals, and Cell Lines.

Fusion <i>n</i>	CRC Series 1 92	CRC Series 2 14	Normal Mucosa Series 2 14	Series 2, Pairs (Positive in Both Tumor and Normal) 14	Tumors, Series 1 + 2 106	Cell Lines 21
<i>AKAP13-PDE8A</i>	15 (16%)	4 (29%)	4 (29%)	2 (14%)	19 (18%)	18 (86%)
<i>CTB35F21.1-PSD2</i>	41 (45%)	8 (57%)	2 (14%)	1 (7%)	49 (46%)	18 (86%)
<i>COMMD10-AP3S1</i>	49 (53%)	12 (86%)	4 (29%)	4 (29%)	61 (58%)	20 (95%)

to detect the small amount of expressed fusion transcripts. The *AKAP13-PDE8A* fusion transcript, originally identified in the SW480 cell line, was positive in 19 of the 106 CRCs (18%) and as well in 4 of the 14 normal colonic mucosa samples (29%; Tables 2 and W6). Of the four positive normal samples, one was also positive for the *COMMD10-AP3S1* fusion transcript, and another sample was also positive for the *CTB-35F21.1-PSD2* fusion transcript. The *COMMD10-AP3S1* fusion transcript, originally identified in the HCT116 cell line, was positive in 61 of the 106 CRCs (58%) and in 4 of the 14 normal colonic mucosa samples (29%). The *CTB-35F21.1-PSD2* fusion transcript, originally identified in the SW480 cell line, was positive in 49 of the 106 CRCs (46%) and in 2 of the 14 normal colonic mucosa samples (14%). Fur-

thermore, *SPAG9-MBTD1* was positive in four cancers (4%) and one normal sample (7%), *NCOA3-SPINT1* was positive in one normal sample (7%), and the remaining five fusion transcripts were negative in all clinical CRC samples (Table W5; Supplementary Materials). The identity of the fusion transcripts were further ensured by Sanger sequencing in 36 samples, confirming the sequence in all, and the chimeric sequences were shown to be located precisely at known exon boundaries in 31 of these (Table W7; Supplementary Materials). Nested PCR on the three fusion transcripts *AKAP13-PDE8A*, *COMMD10-AP3S1*, and *CTB-35F21.1-PSD2* were performed on 20 additional normal tissues of miscellaneous sources. Of the 20 samples, 3, 10, and 17 were positive for the fusions *AKAP13-PDE8A*,




Figure 2. The *AKAP13-PDE8A* fusion transcript is recurrent in CRC, and the genomic locus is rearranged in the SW480 cell line. (A) Twenty-four RNA sequence reads spanned the chimeric transcript breakpoint, passing from exon 1 of *AKAP13* (ENST00000361243) to exon 3 of *PDE8A* (ENST00000310298). Dark colors indicate exons that are not part of the fusion transcript. (B) Genomic view of the rearranged locus, from the top showing annotated exons of the fused genes (exons belonging to genes located between and within *PDE8A* and *AKAP13* were removed for clarification), relative RNA expression levels, and DNA copy numbers. The two latter are based on coverage data from high-throughput sequencing of RNA and DNA from the SW480 cell line. (C) The *AKAP13-PDE8A* fusion transcript was initially detected from the SW480 cell line, but nested RT-PCR demonstrated detectable levels from 17 additional colon cancer cell lines (see Table 2 for cell line identities). The specific breakpoints of the *AKAP13-PDE8A* fusion transcripts were verified by Sanger sequencing and shown to follow the consensus splicing sites of the fusion partner genes.




Figure 3. The *COMMD10-AP3S1* fusion transcript is recurrent in CRC, and the genomic locus is rearranged in the HCT116 cell line. (A) Twelve RNA sequence reads spanned the chimeric transcript breakpoint, passing from exon 4 of *COMMD10* (ENST00000274458) to exon 4 of *AP3S1* (ENST00000316788). Dark colors indicate exons that are not part of the fusion transcript. (B) Genomic view of the rearranged locus, from the top showing annotated exons of the fused genes (exons belonging to genes located between and within *COMMD10* and *AP3S1* were removed for clarification), relative RNA expression levels, and DNA copy numbers. The two latter are based on coverage data from high-throughput sequencing of RNA and DNA from the HCT116 cell line. (C) The *COMMD10-AP3S1* fusion transcript was initially detected from the HCT116 cell line, but nested RT-PCR demonstrated detectable levels in 19 additional colon cancer cell lines (see Table 2 for cell line identities). The specific breakpoints of the *COMMD10-AP3S1* fusion transcripts were verified by Sanger sequencing and shown to follow the consensus splicing sites of the fusion partner genes.

COMMD10-AP3S1, and *CTB-35F21.1-PSD2*, respectively (tissue identities in Table W8).

For the three fusion transcripts with more than 10% positive CRCs, we tested for associations with clinical parameters (stage, MSI status, tumor location, gender, and age) and molecular data (MSI, mutations in *BRAF*, *KRAS*, *PIK3CA*, and *PTEN*, and transcriptome instability [26–28]). None of the associations were statistically significant (data not shown).

Discussion

Here, we report three novel and highly recurrent fusion transcripts in CRC, *AKAP13-PDE8A*, *COMMD10-AP3S1*, and *CTB-35F21.1-PSD2*. Their high prevalence in CRC, as well as their presence in a significant proportion of normal colonic mucosa samples, indicates that they are commonly produced and most often not the result of genomic rearrangement. All three recurrently detected fusion transcripts have partner genes from the same chromosome, suggesting a polymerase read-through mechanism. However, the switch of order of the *AKAP13-PDE8A* implies that this mechanism cannot be the sole explanation, and we see both genomic duplications, which is evident from the SW480 cell line, and trans-splicing as other likely mechanisms. A genomic breakpoint was identified in the *COMMD10-AP3S1* fusion in HCT116, and together with the increased coverage between the breakpoints, this supports a genomic duplication as the

mechanism for these fusion transcripts and cell line. Further, since the genomic PCR covering the breakpoint sequence was only positive for this sample, the *COMMD10-AP3S1* fusion transcript is not likely to be due to a common copy number variant.

In the majority of the positive samples, the fusion transcripts were expressed at low levels, underscored by the need for nested PCR for detection. Originally, using regular one-step PCR, we detected the *CTB-35F21.1-PSD2* fusion transcript in the cell lines SW480 and HCT15. Given also the precise joining of sequences at known exon boundaries, we reason that the measured fusion transcripts are not produced by artifacts of the laboratory protocol. However, the presence of genomic rearrangements of *AKAP13-PDE8A* and *COMMD10-AP3S1* in one cancer cell line each indicates that the production of fusion transcripts may guide the generation of genomic rearrangements, similarly to a previous report on the fusion of *JAZF1* and *JJAZ1* in endometrial stromal tumors [24]. Recently, a study showed that fusion transcripts in healthy cells may also generate fusion proteins [21].

The predicted protein encoded by the *AKAP13-PDE8A* fusion transcript includes only coding parts from the *PDE8A* partner and with a truncation of 72 amino acid residues from its N terminus. *PDE8A* encodes a phosphodiesterase involved in regulation of cyclic adenosine monophosphate (cAMP) metabolism [40]. Five alternative splicing variants have been characterized, with a conserved catalytic domain located toward the C-terminal region, starting on amino acid number 555, located on exon 18 [41]. This suggests that the catalytic

domain is still active in the predicted fusion protein encoded by the *AKAP13-PDE8A* fusion transcript. Interestingly, the protein encoded by *AKAP13* is an A-kinase anchoring protein [42]. Although speculative, the regulation of *PDE8A* by the *AKAP13* promoter may alter cAMP-mediated signaling in cells harboring this fusion. As FISH analysis of the fusion gene did not reveal large-scale structural rearrangements of the region containing both partner genes, the DNA copy number increase suggests some local rearrangement, such as duplication. Importantly, the increased coverage from the whole-genome sequencing data in the SW480 cell line spans the exact region corresponding to the *AKAP13-PDE8A* fusion transcript.

The breakpoint in the *COMMD10-AP3S1* fusion transcript is between exon 5 of *COMMD10* and exon 4 of *AP3S1*. *COMMD10* is predicted to encode a suppressor of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) [43], whereas *AP3S1* encodes a partner of the AP-3 complex, an adapter-related complex that is associated with the Golgi apparatus and more peripheral structures. *AP3S1* facilitates the budding of vesicles from the Golgi membrane and may be directly involved in trafficking to lysosomes [44]. Increased coverage in the *COMMD10-AP3S1* locus from the whole-genome sequence data on HCT116 suggests, as with the *AKAP13-PDE8A* fusion, that a duplication of a segment covering both genes may have caused the fusion and, hence, the DNA copy number change.

The predicted protein encoded by the *CTB-35F21.1-PSD2* fusion transcript includes the first three exons of *CTB-35F21.1*, which is annotated as a lincRNA in the Havana database, and all coding exons of *PSD2*, beginning with the start codon in exon 2. *PSD2* encodes a protein containing pleckstrin and Sec7 domains and is shown to interact with PMS2 in the DNA mismatch repair complex [45].

The prevalence of the identified fusion transcripts may be even higher than what is reported here, as we have only tested the breakpoint between two exons originally identified to be involved in the fusion, and other CRCs may have fusion transcripts between the same genes at another exon at one or both sides of the breakpoint. Furthermore, other CRCs may have one of the fusion partners exchanged for another gene.

Conclusions

We have identified three novel recurrent and seven novel private fusion transcripts in CRC. This adds significantly to the knowledge on chimeric transcripts in CRC and provides a new context for further studies targeted at the usage of fusions as biomarkers or drug targets.

Acknowledgments

We are grateful to Shujun Luo, Irina Khrebtukova, and Gary Schroth from Illumina for providing the RNA sequencing data for the 16 different human tissues ahead of release to the ArrayExpress public data repository.

References

- [1] Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, and Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* **127**, 2893–2917.
- [2] Bacolod MD and Barany F (2011). Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. *Ann Surg Oncol* **18**, 3694–3700.
- [3] Waldner MJ and Neurath MF (2010). The molecular therapy of colorectal cancer. *Mol Aspects Med* **31**, 171–178.
- [4] Skotheim RI and Nees M (2007). Alternative splicing in cancer: noise, functional, or systematic? *Int J Biochem Cell Biol* **39**, 1432–1449.
- [5] Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* **310**, 644–648.
- [6] Kumar-Sinha C, Tomlins SA, and Chinnaiyan AM (2008). Recurrent gene fusions in prostate cancer. *Nat Rev Cancer* **8**, 497–511.
- [7] Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jerónimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, and Teixeira MR (2012). FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. *Genes Chromosomes Cancer* **51**, 240–249.
- [8] Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, et al. (2010). Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nat Med* **16**, 793–798.
- [9] Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demicheli F, et al. (2009). SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. *Cancer Res* **69**, 2734–2738.
- [10] Barros-Silva JD, Paulo P, Bakken AC, Cerveira N, Løvf M, Henrique R, Jerónimo C, Lothe RA, Skotheim RI, and Teixeira MR (2013). Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer. *Neoplasia* **15**, 720–726.
- [11] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S-I, Watanabe H, Kurashina K, Hatanaka H, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* **448**, 561–566.
- [12] Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, et al. (2009). KIF5B-ALK, a novel fusion oncokinas identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. *Clin Cancer Res* **15**, 3143–3149.
- [13] Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, et al. (2012). Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. *Nat Med* **18**, 382–384.
- [14] Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et al. (2012). RET, ROS1 and ALK fusions in lung cancer. *Nat Med* **18**, 378–381.
- [15] Robinson DR, Kalyana-Sundaram S, Wu Y-M, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, et al. (2011). Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. *Nat Med* **17**, 1646–1651, 10.1038/nm.2580.
- [16] Bass AJ, Lawrence MS, Bracci LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Sakseena G, Sivachenko A, et al. (2011). Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. *Nat Genet* **43**, 964–968.
- [17] Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, et al. (2012). Recurrent R-spondin fusions in colon cancer. *Nature* **488**, 660–664.
- [18] Nacu S, Yuan W, Kan Z, Bhatt D, Rivers CS, Stinson J, Peters BA, Modrusan Z, Jung K, Seshagiri S, et al. (2011). Deep RNA sequencing analysis of read-through gene fusions in human prostate adenocarcinoma and reference samples. *BMC Med Genomics* **4**, 11.
- [19] Zhang Y, Gong M, Yuan H, Park HG, Frierson HF, and Li H (2012). Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. *Cancer Discov* **2**, 598–607.
- [20] Djebali S, Lagarde J, Kapranov P, Lacroix V, Borel C, Mudge JM, Howald C, Foissac S, Ucla C, Chrast J, et al. (2012). Evidence for transcript networks composed of chimeric RNAs in human cells. *PLoS One* **7**, e28213.
- [21] Frenkel-Morgenstern M, Lacroix V, Ezkurdia I, Levin Y, Gabashvili A, Prilusky J, del Pozo A, Tress M, Johnson R, Guigó R, et al. (2012). Chimeras taking shape: potential functions of proteins encoded by chimeric RNA transcripts. *Genome Res* **22**, 1231–1242.
- [22] Plebani R, Oliver GR, Trerotola M, Guerra E, Cantanelli P, Apicella L, Emerson A, Albiero A, Harkin PD, Kennedy RD, et al. (2012). Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNA. *Neoplasia* **14**, 1087–1096.
- [23] Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al. (2012). Landscape of transcription in human cells. *Nature* **489**, 101–108.

- [24] Li H, Wang J, Mor G, and Sklar J (2008). A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. *Science* **321**, 1357–1361.
- [25] Kleivi K, Teixeira MR, Eknaes M, Diep CB, Jakobsen KS, Hamelin R, and Lothe RA (2004). Genome signatures of colon carcinoma cell lines. *Cancer Genet Cytogenet* **155**, 119–131.
- [26] Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, and Lothe RA (2003). Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. *J Clin Oncol* **21**, 820–829.
- [27] Berg M, Danielsen SA, Ahlquist T, Merok MA, Ågesen TH, Vatn MH, Mala T, Sjo OH, Bakka A, Moberg I, et al. (2010). DNA sequence profiles of the colorectal cancer critical gene set *KRAS-BRAF-PIK3CA-PTEN-TP53* related to age at disease onset. *PLoS One* **5**, e13978.
- [28] Sveen A, Ågesen TH, Nesbakken A, Rognum TO, Lothe RA, and Skotheim RI (2011). Transcriptome instability in colorectal cancer identified by exon microarray analyses: associations with splicing factor expression levels and patient survival. *Genome Med* **3**, 32.
- [29] McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MGF, Griffith M, Heravi Moussavi A, Senz J, Melnyk N, et al. (2011). deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. *PLoS Comput Biol* **7**, e1001138.
- [30] Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, and Pachter L (2010). Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol* **28**, 511–515.
- [31] Trapnell C, Pachter L, and Salzberg SL (2009). TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* **25**, 1105–1111.
- [32] Langmead B, Trapnell C, Pop M, and Salzberg SL (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* **10**, R25.
- [33] R Development Core Team (2009). *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria.
- [34] Durinck S, Bullard J, Spellman PT, and Dudoit S (2009). GenomeGraphs: integrated genomic data visualization with R. *BMC Bioinformatics* **10**, 2.
- [35] Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol* **5**, R80.
- [36] Rozen S and Skaletsky H (2000). Primer3 on the WWW for general users and for biologist programmers. *Methods Mol Biol* **132**, 365–386.
- [37] Li H and Durbin R (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760.
- [38] Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, and Mesirov JP (2011). Integrative genomics viewer. *Nat Biotechnol* **29**, 24–26.
- [39] McPherson A, Wu C, Wyatt AW, Shah S, Collins C, and Sahinalp SC (2012). nFuse: discovery of complex genomic rearrangements in cancer using high-throughput sequencing. *Genome Res* **22**, 2250–2261.
- [40] Fisher DA, Smith JF, Pillar JS, St Denis SH, and Cheng JB (1998). Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. *Biochem Biophys Res Commun* **246**, 570–577.
- [41] Wang P, Wu P, Egan RW, and Billah MM (2001). Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. *Gene* **280**, 183–194.
- [42] Diviani D, Soderling J, and Scott JD (2001). AKAP-Lbc anchors protein kinase A and nucleates $G\alpha_{12}$ -selective Rho-mediated stress fiber formation. *J Biol Chem* **276**, 44247–44257.
- [43] Burstein E, Hoberg JE, Wilkinson AS, Rumble JM, Csomos RA, Komarck CM, Maine GN, Wilkinson JC, Mayo MW, and Duckett CS (2005). COMMD proteins, a novel family of structural and functional homologs of MURR1. *J Biol Chem* **280**, 22222–22232.
- [44] Simpson F, Peden AA, Christopoulou L, and Robinson MS (1997). Characterization of the adaptor-related protein complex, AP-3. *J Cell Biol* **137**, 835–845.
- [45] Cannavo E, Gerrits B, Marra G, Schlapbach R, and Jiricny J (2007). Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2. *J Biol Chem* **282**, 2976–2986.

Table W1. Clinical Data from the Two Patient Cohorts.

	Series 1	Series 2	Combined
No. of patients	92	14	106
Age			
Mean	65.3	75.4	66.6
Gender			
Women	51	5	56
Men	41	9	50
Tumor localization			
Colon	54	14	
Rectum	38		
T stage			
T2	50	2	52
T3	42	11	53
T4	0	1	1
MSI status			
MSI	14	6	20
MSS	77	8	85
NA	1	0	1

A total of 106 patients, from two cohorts, were used in validating the fusions. The cohorts were enriched for patients with stage II or stage III CRC.

Table W2. Number of Paired RNA Sequence Reads that Passed the Illumina Chastity Filtering and the Number of Reads that Aligned to the Reference Genome hg19, Using TopHat v1.3.3 and Bowtie 0.12.7, for Each of the Seven Cell Lines on the Illumina Genome Analyzer IIX Instrument.

Cell Line	Filtered Clusters (M)	Reads Aligned (M)
HT29	33.9	61.3
HCT15	31.3	43.8
SW480	33.5	54.6
SW48	23.4	32.6
HCT116	32.1	46.8
LS1034	31.4	34.1
RKO	37.6	61.7

Table W3. Oligonucleotide Primers Used in RT-PCR to Validate the Fusion Transcripts.

Fusion Transcript	Cell Line with Indication from RNA Sequence Data	Forward Primer	Reverse Primer
<i>MGRN1-C16orf96</i>	HCT15	TGCAGGACTTGCTCACTGAT	GCTGCAGTGCAACCATCTT
<i>NCOA3-SPINT1</i>	HCT15	TAAAGCTGAGCTGCGAGGAA	GTGCACAGAAGCCACAAGG
<i>PRMT1-FLT3LG</i>	HCT15	TACCGTCAAGGTGGAAGACC	GAAGTTCTGGCGAGTGATCC
<i>COMMD10-AP3S1</i>	HCT116	CAGCTTTGCAGCAGCAATTA	TGTGCATCAATTTGTGTAACAATC
<i>COMMD10-AP3S1*</i>	HCT116	CAAAGCTGAAGCATTTGTCA	CCCATCACCAATTTCTGCAAG
<i>COMMD10-AP3S1[†]</i>	HCT116	GCCACCCAGTTTATGCTTG	GCAAGACCAAGAGGTTTGTATG
<i>SPAG9-MBTD1</i>	HCT116	GTGCTGGAGAACCTGGACTC	CCATTCCCCTCTGGTCTA
<i>SLC39A14-TSPAN15</i>	HT29	CTGCCTGGACCTCCTCTTTC	GGACTACCGAGATTGGAGCA
<i>AKAP13-PDE8A</i>	SW480	GCGAAGGTGAAGAGTTGTCC	AACCCCTGCTTTTTCACATGC
<i>AKAP13-PDE8A*</i>	SW480	TGTGCTCTGCCGAGACTG	AGCCTGAGCCTCCTTGGTA
<i>CTB-35F21.1-PSD2</i>	SW480	AGAGCTCCTCACCTGTTCCA	TCCTCAGGCACTGCAGATAA
<i>CTB-35F21.1-PSD2*</i>	SW480	GTGTCTCCTGAGCCCACTCC	TCACTGGCCATCCCATTTC
<i>FAM96A-STIM1</i>	SW480	CTGGAAGTGGTCTCGGAAAG	TCAGCCACTGTACCACCTCA
<i>GRIN2B-CYP4F3</i>	SW480	ATTCCCAACATGCTCACTCC	GCATCACTCCTGGGTGTCTT

*Primers used in nested RT-PCR.

[†]Primers used for testing the genomic breakpoint.**Table W4.** By Using Five Filtering Steps, the Number of Candidate Fusions was Reduced from 3391 to 11.

Sample	Unfiltered Fusions	Normal	Ribosomal	Promiscuous	Intrachromosomal <100 kb	Not Exon Boundaries
(A) The number of potential fusions in the sequenced cell lines, before and after the five filtering steps						
RKO	999	880	397	45	40	1
HCT15	705	586	358	36	27	1
HCT116	693	545	207	41	31	2
SW480	506	406	220	43	37	6
LS1034	381	293	128	31	26	0
HT29	75	34	15	14	10	1
SW48	32	3	2	2	2	0
All	3391	2747	1328	212	173	11
(B) The number of potential fusions in the sequenced cell lines applying each filter separately						
RKO	999	880	418	72	897	96
HCT15	705	586	390	71	635	75
HCT116	693	545	228	59	586	79
SW480	506	406	235	136	433	64
LS1034	381	293	137	55	332	42
HT29	75	34	20	35	56	14
SW48	32	3	3	6	17	6
All	3391	2747	1431	434	2956	376

Table W6. The Presence of Fusion Transcripts in the 14 Matched Tumor-Normal Samples from Series 2.

Series 2 Pair	<i>AKAP13-PDE8A</i>		<i>CTB-35F21.1-PSD2</i>		<i>COMMD10-AP3S1</i>	
	Tumor	Normal	Tumor	Normal	Tumor	Normal
1	N	N	N	N	Y	N
2	N	N	N	N	Y	Y
3	N	N	Y	Y	Y	N
4	N	N	Y	N	Y	N
5	Y	N	N	N	N	N
6	N	N	Y	N	Y	N
7	N	N	N	N	Y	Y
8	N	N	Y	N	Y	N
9	Y	Y	N	Y	Y	N
10	N	N	Y	N	Y	Y
11	N	Y	Y	N	Y	N
12	N	N	N	N	N	N
13	N	Y	N	N	Y	Y
14	Y	Y	Y	N	Y	N

Table W7. Sequence Validation of Nested PCR Products was Performed on Altogether 36 Samples Positive for either of the Identified Fusion Transcripts.

Fusion Transcript	Positive Samples Confirming the Identity of Both Partner Genes
<i>COMMD10-AP3S1</i>	7/7 (100%)
<i>CTB-35F21.1-PSD2</i>	6/6 (100%)
<i>AKAP13-PDE8A</i>	5/6 (83%)
<i>SPAG9-MBTD1</i>	2/4 (50%)
<i>NCOA3-SPINT1</i>	2/3 (67%)
<i>PRMT1-FLT3LG</i>	7/8 (88%)
<i>MGRN1-C16orf96</i>	2/2 (100%)

Table W8. The Presence of Fusion Transcripts in 20 Normal RNA Samples.

Sample	<i>AKAP13-PDE8A</i>	<i>COMMD10-AP3S1</i>	<i>CTB-35F21.1-PSD2</i>
Adipose	N	N	Y
Bladder	N	N	Y
Brain	N	N	Y
Cervix	N	N	Y
Colon	Y	Y	Y
Esophagus	N	Y	Y
Heart	N	N	N
Kidney	N	N	Y
Liver	N	Y	Y
Lung	Y	N	Y
Ovary	N	Y	Y
Placenta	N	Y	Y
Prostate	N	N	Y
Skeletal muscle	N	N	Y
Spleen	N	Y	Y
Stomach	N	N	N
Testes	Y	Y	Y
Thymus	N	Y	Y
Thyroid	N	Y	N
Trachea	N	Y	Y